Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Palvella Therapeutics, Inc. - Common Stock (NQ:PVLA)

71.92 +1.49 (+2.12%)
Streaming Delayed Price Updated: 10:21 AM EDT, Oct 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Palvella Therapeutics, Inc. - Common Stock

Palvella Therapeutics Inc (NASDAQ:PVLA) Reports Wider Q2 2025 Loss, Stock Drops 13% Despite Clinical Progress
Palvella Therapeutics (PVLA) reported a Q2 2025 net loss of $0.86 per share, missing estimates. Revenue was $0.0 as expected, with $70.4M cash on hand. Stock fell 13% pre-market despite clinical... 
Via Chartmill
Palvella Posts Cash Gain and Trial Wins
Via The Motley Fool
Topics Intellectual Property
Earnings Scheduled For August 14, 2025
 
Via Benzinga
This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
 
Via Benzinga
This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
Earnings Scheduled For May 15, 2025
 
Via Benzinga
This Couchbase Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
 
Via Benzinga
Earnings Scheduled For March 31, 2025
 
Via Benzinga
Pavella - Undiscovered Biotechnology Stock
The company focuses on developing therapies for rare genetic skin diseases, with its lead product QTORIN rapamycin in advanced clinical trials. 
Via Talk Markets
Topics Stocks / Equities
This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
 
Via Benzinga
This Intuitive Machines Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Wednesday
 
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.